Animation - Understanding Immunotherapy for NSCLC with PD-1 and PD-L1 Biomarkers
This animation provides an overview of immunotherapy for non-small cell lung cancer (NSCLC) with PD-1 and PD-L1 biomarkers. The option of immunotherapy is one more reason why everyone diagnosed with NSCLC should have biomarker testing. Watch to learn about PD-1, PD-L1, and CTLA-4 checkpoint proteins, and the different immune checkpoint inhibitor drugs that act on PD-1, PD-L1, and CTLA-4. You can also learn about finding a clinical trial if you have PD-1, PD-L1, or CTLA-4.
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about lung cancer which will help other patients, caregivers and families.
Animation - Understanding Immunotherapy for NSCLC with PD-1 and PD-L1 Biomarkers
Slide Show - Understanding Immunotherapy for NSCLC with PD-1 and PD-L1 Biomarkers
1.
What is immunotherapy and how does it work for lung cancer?
2.
What types of immunotherapy are used to treat lung cancer?
3.
What side effects can be associated with immunotherapy for lung cancer?
